Ukendt tidspunkt for indsættelsestidspunkt for apopleksi med reperfusion uden avanceret billeddannelse (UTOPIA)
Intravenøs Tenekteplase til Akut Iskæmisk Apopleksi med Ukendt Symptomstartstidspunkt Under Uden Kontrastmiddel CT-selektion: Et Multicenter, Prospektivt, Randomiseret, Åbent, Blindet Endpunktsforsøg
The benefit of intravenous tenecteplase for acute ischemic stroke with unknown time of onset, e.g. wake-up stroke, remains uncertain. This randomized study aims to assess the efficacy and safety of intravenous tenecteplase following non-contrast CT screening for acute ischemic stroke with unknown time of onset.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
UTOPIA is an investigator-initiated, multicenter, prospective, randomized, open-label, blinded endpoint (PROBE) trial that aims to assess the efficacy and safety of intravenous tenecteplase for acute ischemic stroke with unknown time of onset, selected by non-contrast CT. The primary outcome is excellent outcome, as defined by a score of 0 or 1 on modified Rankin Scale (mRS) at 90 days.
Participants randomized to the intervention group will receive intravenous tenecteplase at 0.25 mg/kg with a maximum dose of 25 mg and standard medical treatment, and those randomized to the control group will receive standard medical treatment only, without intravenous thrombolysis.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Dong Pan, MD, PhD
- Telefonnummer: 86-156 2648 3251
- E-mail: dongpan012@hotmail.com
Studiesteder
-
-
Fujian
-
Xiamen, Fujian, Kina, 361004
- Ikke rekrutterer endnu
- Zhongshan Hospital of Xiamen University
-
Kontakt:
- Xingyu Chen
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510620
- Ikke rekrutterer endnu
- Guangzhou Twelfth People's Hospital
-
Kontakt:
- Jianwu Dai
-
-
Guangxi
-
Baise City, Guangxi, Kina, 533000
- Ikke rekrutterer endnu
- Baise People's Hospital
-
Kontakt:
- Dengxing Li
-
Chongzuo, Guangxi, Kina, 532200
- Rekruttering
- The People's Hospital of Chongzuo
-
Kontakt:
- Jianyi Huang
-
Guigang, Guangxi, Kina, 537121
- Ikke rekrutterer endnu
- People's Hospital of Qintang District, Guigang City
-
Kontakt:
- Jixin Lu
-
Guigang, Guangxi, Kina, 537200
- Ikke rekrutterer endnu
- Guiping People's Hospital
-
Kontakt:
- Peiquan Yang
-
Laibin, Guangxi, Kina, 545900
- Ikke rekrutterer endnu
- Wuxuan County People's Hospital
-
Kontakt:
- Yu Huang
-
Liuzhou, Guangxi, Kina, 545007
- Ikke rekrutterer endnu
- Liuzhou Workers' Hospital
-
Kontakt:
- Liya Pan
-
Nanning, Guangxi, Kina, 530021
- Ikke rekrutterer endnu
- The First Affiliated Hospital of Guangxi Medical University
-
Kontakt:
- Dong Pan, MD, PhD
- Telefonnummer: 86-156 2648 3251
- E-mail: dongpan012@hotmail.com
-
Ledende efterforsker:
- Yuan Wu, MD, PhD
-
Nanning, Guangxi, Kina, 530200
- Ikke rekrutterer endnu
- Nanning Yongning District People's Hospital
-
Kontakt:
- Wuqiao Liang
-
Kontakt:
- Qihai Zhou
-
Nanning, Guangxi, Kina, 530219
- Ikke rekrutterer endnu
- Guangxi Medical University Kaiyuan Langdong Hospital
-
Kontakt:
- Kai Chen
-
Nanning, Guangxi, Kina, 530409
- Ikke rekrutterer endnu
- No.9 People's Hospital of Nanning
-
Kontakt:
- Jun Qu
-
Qinzhou, Guangxi, Kina, 535000
- Ikke rekrutterer endnu
- The Second People's Hospital of Qinzhou
-
Kontakt:
- Caixia Xuan
-
-
Shaanxi
-
Yulin, Shaanxi, Kina, 718100
- Ikke rekrutterer endnu
- Mizhi County Hospital
-
Kontakt:
- Tao Zhang
-
Yulin, Shaanxi, Kina, 718600
- Ikke rekrutterer endnu
- Dingbian County People's Hospital
-
Kontakt:
- Gaiyan Qu
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age ≥ 18 years old.
- Clinical diagnosis of acute ischemic stroke.
- Unknown time of stroke onset (e.g., stroke symptom recognized on awakening) but last-known normal time >4.5 hours.
- Time from stroke symptom recognition (e.g., awakening) to randomization within 3 hours.
- National Institutes of Health Stroke Scale (NIHSS) score of 6-25 (both inclusive).
- Pre-stroke modified Rankin Scale (mRS) score of 0-1.
- Written informed consent from patients or their legally authorized representatives.
Exclusion Criteria:
- Intracranial hemorrhage confirmed by skull CT, or history of intracranial hemorrhage.
- Planned endovascular treatment.
- Rapid neurological improvement with NIHSS <6 at randomization.
- Allergy to tenecteplase.
- Use of vitamin K antagonist with INR >1.7, use of heparin or low molecular heparin in the past 24 hours, or use of direct oral anticoagulants in the past 48 hours.
- Hypodensity on non-contrast CT >1/3 middle cerebral artery territory.
- Severe traumatic brain injury or other major trauma in the past 3 months.
- Intracranial neoplasm, arteriovenous malformation, or aneurysm (≥10mm).
- Intracranial surgery, intraspinal surgery, or other major surgery in the past 3 months.
- Gastrointestinal or urinary tract hemorrhage in the past 3 weeks.
- Active internal bleeding.
- Aortic dissection.
- Infective endocarditis.
- Platelet count <100×10^9/L.
- Women who are pregnant or breastfeeding.
- Blood glucose <50 or >400 mg/dL (<2.78 or >22.2 mmol/L).
- Systolic blood presure >185 mmHg or diastolic blood presure >110 mmHg refractory to treatment.
- Life expectancy <3 months.
- Participating in other trials.
- Any condition that, in the judgment of the investigator, makes the patient unsuitable for this study or where this study may impose a significant risk to the patient (e.g., inability to understand and/or comply with study procedures and/or follow-up due to psychiatric disorders, cognitive or emotional impairment).
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Andet: Control group
Standard Medical Treatment |
Standard medical treatment should adhere to clinical guidelines and usual care at site, including antiplatelet therapy, anticoagulant therapy, lipid-lowering therapy, antihypertensive drugs, etc., as determined by the local investigators. |
|
Eksperimentel: Tenecteplase group
Intravenous tenecteplase thrombolysis |
Standard medical treatment should adhere to clinical guidelines and usual care at site, including antiplatelet therapy, anticoagulant therapy, lipid-lowering therapy, antihypertensive drugs, etc., as determined by the local investigators. Tenecteplase is administered as a single intravenous bolus at a dose of 0.25 mg/kg, with a maximum of 25 mg, administered as soon as possible after the randomization. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Excellent outcome
Tidsramme: 90 (±14) days
|
The proportion of modified Rankin Scale (mRS) score of 0-1 at 90 days |
90 (±14) days
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Level of disability
Tidsramme: 90 (±14) days
|
Ordinal shift analysis of the mRS with 5-6 merged at 90 days. |
90 (±14) days
|
|
Functional independence
Tidsramme: 90 (±14) days
|
The proportion of mRS score of 0-2 at 90 days. |
90 (±14) days
|
|
Early neurological improvement
Tidsramme: 24 (±12) hours
|
The proportion of NIHSS 0-1 or ≥4 points reduction at 24 (±12) hours. |
24 (±12) hours
|
|
Change in stroke severity
Tidsramme: 7 (±1) days or at discharge
|
The change of NIHSS score from baseline to 7 days or at discharge (whichever comes first) |
7 (±1) days or at discharge
|
|
Quality of life measured by EQ-5D-5L
Tidsramme: 90 (±14) days
|
EQ-5D-5L scale score at 90 days. |
90 (±14) days
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Symptomatic intracranial hemorrhage
Tidsramme: 24 (±12) hours
|
Incidence of symptomatic intracranial hemorrhage within 36 hours from randomization (Heidelberg criteria) |
24 (±12) hours
|
|
Any intracranial hemorrhage
Tidsramme: 24 (±12) hours
|
Incidence of any intracranial hemorrhage within 36 hours from randomization (Heidelberg classification) |
24 (±12) hours
|
|
Extracranial bleeding
Tidsramme: 24 (±12) hours
|
Incidence of moderate-to-severe extracranial bleeding (GUSTO criteria) within 36 hours from randomization |
24 (±12) hours
|
|
Mortality
Tidsramme: 90 days
|
All cause death within 90 days. |
90 days
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: Yuan Wu, MD, PhD, First Affiliated Hospital of Guangxi Medical University
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Cerebrovaskulære lidelser
- Hjernesygdomme
- Sygdomme i centralnervesystemet
- Sygdomme i nervesystemet
- Karsygdomme
- Hjerte-kar-sygdomme
- Slag
- Iskæmisk slagtilfælde
- Aminosyrer, peptider og proteiner
- Proteiner
- Hydrolaser
- Enzymer
- Enzymer og coenzymer
- Blodproteiner
- Endopeptidaser
- Peptidhydrolaser
- Serinendopeptidaser
- Serinproteaser
- Plasminogenaktivatorer
- Blodkoagulationsfaktorer
- Vævsplasminogenaktivator
- Tenecteplase
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 2026-K0237
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Data supporting the findings of the study are available on reasonable request after approval of a proposal from the principal investigator.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- CSR
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .